Page last updated: 2024-12-07

mannosamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

mannosamine: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

D-mannosamine : The D-enantiomer of mannosamine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

2-amino-2-deoxy-D-mannopyranose : A D-mannosamine in cyclic pyranose form. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID440049
CHEMBL ID4551840
CHEBI ID62325
CHEBI ID62324
SCHEMBL ID438195
MeSH IDM0052055

Synonyms (30)

Synonym
d-mann
d-mannopyranose, 2-amino-2-deoxy-
mannopyranose, 2-amino-2-deoxy-
2-amino-2-deoxymannopyranose
mannopyranose, 2-amoino-2-deoxy-, d-
d-mannosamine
C03570
2-amino-2-deoxy-d-mannose
mannosamine
(3s,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol
2-amino-2-deoxy-d-mannopyranose
CHEBI:62325 ,
MANN ,
EPITOPE ID:153203
SCHEMBL438195
2-amino-2-deoxy-mannose
2-amino-2-deoxy-d-mannopyranoside
2-deoxy-2-amino-d-mannopyranoside
2-amino-2-deoxy-mannopyranose
2-deoxy-2-amino-mannopyranose
2-deoxy-2-amino-d-mannose
2-deoxy-2-amino-d-mannopyranose
2-amino-2-deoxy-mannopyranoside
2-deoxy-2-amino-mannose
2-deoxy-2-amino-mannopyranoside
Q27131768
D-MANNOSAMINES ,
CHEMBL4551840
EN300-19661205
chebi:62324

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" An unsaturated fatty acid (oleate) caused an increase in lipid fluidity of the surface membrane in MOLT-4 lymphoid cells, which possess higher lipid fluidity in combination with mannosamine, while saturated fatty acids had no effect on the fluidity properties of the membrane lipids (even in the presence of mannosamine)."( Antitumor activity of D-mannosamine in vitro: cytotoxic effect produced by mannosamine in combination with free fatty acids on human leukemia T-cell lines.
Harada, T; Morikawa, K; Morikawa, S; Onoda, T, 1985
)
0.27

Bioavailability

ExcerptReferenceRelevance
"57 folds higher oral bioavailability through EPI-PNPs and EPI-MNPs when compared with EPI-S."( Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations.
Alam, MA; Panda, AK; Singh, AT; Talegaonkar, S; Tariq, M, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" The potential for cytotoxic effects at higher concentrations underscores the importance of establishing appropriate dosage regimens for these aminomonosaccharides."( Comparison of inhibitory effects of glucosamine and mannosamine on bovine articular cartilage degradation in vitro.
Caron, JP; Mello, DM; Nielsen, BD; Orth, MW; Peters, TL, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
D-mannosamineThe D-enantiomer of mannosamine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (140)

TimeframeStudies, This Drug (%)All Drugs %
pre-199026 (18.57)18.7374
1990's25 (17.86)18.2507
2000's40 (28.57)29.6817
2010's42 (30.00)24.3611
2020's7 (5.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (1.39%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other142 (98.61%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]